2020
Optimizing Care for Patients With Adverse Events From Immunotherapeutics.
Sheehan K, Price C, Hafez N. Optimizing Care for Patients With Adverse Events From Immunotherapeutics. The Cancer Journal 2020, 26: 537-542. PMID: 33298725, DOI: 10.1097/ppo.0000000000000492.BooksConceptsImmune checkpoint inhibitorsAdverse eventsCheckpoint inhibitorsImmune therapyGuideline-driven managementMajority of irAEsSteroid-refractory casesRisk patientsOptimal carePredictive biomarkersTumor boardIrAEsWellness clinicPatientsEarly detectionTranslational researchTherapyCareCommon occurrenceInhibitorsImmunotherapeuticsClinicSteroidsImmuneBiomarkers
2015
Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long?
Barmettler S, Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? Journal Of Allergy And Clinical Immunology 2015, 136: 1407-1409. PMID: 26277594, DOI: 10.1016/j.jaci.2015.06.035.Peer-Reviewed Original Research